Ringside sends Immunome towards filing
On a cross-trial basis varegacestat beats Ogsiveo.
J-Pharma chases Telix in LAT1
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
There’s no stopping CDH17
No fewer than four ADCs with this target start human testing.
Baili moves its CD33 conjugate into advanced trials
The company is set to start a phase 2/3 trial this month.
AstraZeneca becomes TIGIT's last man standing
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Bristol challenges Adcetris on its own turf
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
SABCS 2025 – Ember-3 brings no all-comers solace
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
